Citi analyst Yigal Nochomovitz added an \"upside 30-day catalyst watch\" on shares of Zenas BioPharma while keeping a Buy rating on the name with a $41 price target. The Q1 report indicate obexelimab remains on track for an application submission to the FDA in Q2, the analyst tells investors in a research note. Citi believes obexelimab is positioned for approval following the positive INDIGO data. It sees current share levels as an attractive entry point.
